Reauthorizes funding for children's hospitals' graduate medical education programs through 2030, while prohibiting funds from being used for gender-altering procedures and drugs for individuals under 18, with exceptions for certain medical conditions and emergencies.
Dan Crenshaw
Representative
TX-2
The "Children's Hospital GME Support Reauthorization Act of 2025" extends funding for graduate medical education programs at children's hospitals through 2030. It stipulates that hospitals providing gender-altering procedures and drugs to minors will not receive payments, defining these procedures while providing specific exceptions. The act allocates \$124,000,000 and \$261,000,000 for each fiscal year from 2026 through 2030 and defines "sex" as determined at birth.
This bill renews federal funding for medical training programs at children's hospitals but adds a significant condition. The Children's Hospital GME Support Reauthorization Act of 2025 extends payments for graduate medical education (GME) programs through fiscal year 2030, allocating a combined $385 million per year ($124M + $261M) for fiscal years 2026 through 2030. However, it also prohibits these payments to hospitals that provide certain specified gender-altering procedures and drugs to patients under 18, starting after December 31, 2025.
The core positive here is the continuation of the Children's Hospital GME program. Think of this as the funding that helps train the pediatric specialists—the surgeons, cardiologists, oncologists—who handle complex kids' health issues. Renewing this support through 2030 means these specialized hospitals can keep their residency and fellowship programs running, which is crucial for maintaining a pipeline of doctors trained to care for children. For most families needing specialized hospital care for their kids, this continued funding is good news, aiming to ensure highly trained staff are available.
The major shift comes with the new strings attached to this funding. Under Section 2, hospitals receiving these GME payments are barred from providing a specific list of procedures and drugs intended to align a minor's body with a different sex. This includes various surgeries (like hysterectomies, mastectomies, phalloplasty) and medications like puberty blockers or hormone treatments (estrogen, testosterone) when used for gender transition purposes.
There are exceptions, such as treatments for medically verified conditions like precocious puberty or certain genetic disorders of sex development, or emergency procedures to prevent death or serious harm (provided the purpose isn't gender alteration). The bill also explicitly states that providing mental or behavioral health services for gender dysphoria doesn't trigger the funding cutoff, as long as it doesn't involve the prohibited physical interventions. Additionally, the bill defines "sex" based on biological characteristics present at birth, including chromosomes, hormones, and reproductive anatomy.
This legislation creates a direct crossroads for children's hospitals that currently offer the types of gender-affirming care listed in the bill. They will need to decide whether to cease providing these specific services to minors or forgo the federal GME funding. This could significantly impact access to care for transgender and gender-nonconforming youth and their families seeking these specific medical interventions.
While the bill aims to ensure continued training for pediatric specialists broadly, the restriction introduces a major policy change tied to a specific type of medical care. Hospitals will need to navigate the definitions and exceptions carefully. For families, this means the availability of certain services at major children's hospitals could change depending on how institutions respond to these new funding conditions starting in late 2025.